X4 Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

X4 Pharmaceuticals

07/05/2024 14:53

* X4 Pharmaceuticals Inc  XFOR.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of -16 cents.  The mean expectation of seven analysts for
the quarter was for a loss of 16 cents per share. Wall Street
expected results to range from -22 cents to -14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * X4 Pharmaceuticals Inc's reported EPS for the quarter was
a loss
of 26 cents​.
    * The company reported a quarterly loss of $51.77 million.
    * X4 Pharmaceuticals Inc shares had fallen by 13.7% this
quarter and gained 43.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $5.00 
This summary was machine generated from LSEG data May 7 at 01:53
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.16          -0.26          Missed
 Dec. 31 2023      -0.15          -0.10          Beat
 Sep. 30 2023      -0.15          -0.01          Beat
 Jun. 30 2023      -0.16          -0.33          Missed